Can an app keep young people with cancer genes on track?

NCT ID NCT06654466

Ongoing Disease control Sponsor: Nest Genomics Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This study tests a software platform called Nest that helps young adults (ages 18-49) with inherited cancer risks manage their care. Participants will use the tool to track screening and share information with doctors and family. Researchers will compare users to non-users to see if the tool improves knowledge, reduces distress, and boosts follow-through on recommended cancer screenings.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nest software platform (electronic medical record-integrated tool for genetics-based care)
What this could lead to: If it works, this could help young adults with inherited cancer risks stay on top of recommended screenings and feel less anxious about their health.
What could go wrong: This is a small, early-stage trial (100 people) testing a software tool, not a treatment. It may not show clear benefits or work outside the specific hospital setting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLINICAL DECISION SUPPORT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hereditary neoplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLINICAL DECISION SUPPORT HEREDITARY CANCER SYNDROMES

Contacts and locations

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.